Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Spiradenocarcinoma Mimicking Basal Cell Carcinoma Incidentally Discovered During Mohs Micrographic Surgery
Wang, Katherine , Barbosa, Naiara S. , Sluzevich, Jason C. , Degesys, Catherine A. , Wang, Katherine L , Sluzevich, Jason C

Mayo Clinic

Dermatologic Surgery | April 8, 2025 | Volume: 51 | Issue: 8 | Pages: 813-815

10.1097/dss.0000000000004637 | PMID 40197612 Get It

Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis Presenting with Neuromyopathy (P7-11.019)
Chen, Yuting , Wang, Han

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212552 Get It

Person-Centered Care and Trial Design for Progressive Supranuclear Palsy: A Collaborative Project of AFTD and CurePSP (P8-3.020)
Dodge, Shana , Shurer, Jessica , Ali, Farwa , Lin, Chi-Ying , Rojas-Martinez, Julio, Wang, Catherine, Wills, Anne‐Marie , Diaz, Kristophe , Irwin, David J. , Kremen, Sarah , VandeVrede, Lawren , Dacks, Penny A.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210658 Get It

Quantitative Retinal Vascular Features as Biomarkers for CADASIL: A Case-Control Study from the UK Biobank (P9-13.003)
Vallamchetla, Sai Krishna , Badr, Amro , Li, Xin , Dumitrascu, Oana M. , Abdelkader, Omar, Shourav, Md Manjurul Islam , Wang, Yalin , Meschia, James F. , Lin, Michelle

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212039 Get It

Antidepressant Non-refill as a Proxy Measure for Medication Acceptability in Electronic Health Records
Sánchez-Ruiz, Jorge A. , Solares-Bravo, Melissa , Jenkins, Gregory D. , Núñez, Nicolás A. , Leibman, Nicole I. , Ahmed, Ahmed T. , Weinshilboum, Richard M. , Wang, Liewei , Frye, Mark A. , Bielinski, Suzette , Weinshilboum, Richard M. , Frye, Mark , Biernacka, Joanna , Ozerdem, Aysegul , Sanchez-Ruiz, Jorge A , Solares‐Bravo, Melissa , Bielinski, Suzette J. , Biernacka, Joanna M. , Özerdem, Ayşegül

Mayo Clinic

Journal of Clinical Psychopharmacology | April 7, 2025 | Volume: 45 | Issue: 4 | Pages: 310-319

10.1097/jcp.0000000000002001 | PMID 40193626 Get It

Abstract Background: Pharmacogenomic studies on antidepressant treatment outcomes could be conducted using previously collected data from electronic health record (EHR)-linked biobanks. However, absence of EHR based outcome measures is an unmet need in designing such studies We aimed to define EHR-derived antidepressant outcome measures and explore their utility in showing associations between treatment outcomes and Cytochrome P450 (CYP) metabolizer phenotypes in a proof-of-concept study. Methods: Using data from the EHR-linked cohort, Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment (RIGHT 10K) Study, we collected prescription data and patient health questionnaire 9 (PHQ-9) scores to compute 3 proxy measures for antidepressant response, efficacy, and acceptability: change in PHQ-9 scores, longest treatment interval with a single antidepressant, and antidepressant non-refill. Subsequently, we tested the association of both prescription-based outcomes with DNA-predicted CYP metabolizer phenotypes in European-ancestry participants. Results: We identified 3920 RIGHT 10K participants with at least 1 antidepressant prescription and European-ancestry. Participants had a mean age of 61 years and 72% were women. Implementation of the PHQ-9 outcome was not feasible because of missingness. Of both prescription-based outcomes, antidepressant non-refill reproduced several known antidepressant-CYP interactions. However, the pilot was limited by small subgroups of participants with non-normal metabolizer phenotypes. Conclusions: Derived from structured data, antidepressant non-refill is a promising outcome measure for EHR-linked biobanks that partially reproduced antidepressant-CYP interactions. However, testing on larger datasets is necessary to understand whether it would be a useful for pharmacogenomic research.
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Rankin, Alexander W. , Hoang, Chloe, Semchenkova, Alexandra , Myers, Regina M. , Wang, Hao‐Wei , Kovach, Alexandra E. , Yuan, Constance M. , Colon, Dana Delgado, Vasseur, Loïc , John, Samuel , Lyons, Kaylyn Utley , Friedes, Barbara D., Alonso‐Saladrigues, Anna , Abdel‐Azim, Hisham , Balducci, Estelle , Aljudi, Ahmed Assim , Balsat, Marie , Biery, D. N. , Chamdin, Aghiad, Cuevo, Raymund S., Dickens, David S. , Duffner, Ulrich, Elliott, Michelle A. , Escherich, Gabriele , Fernandes, Sneha, Fitzjohn, Mandi R., Gahvari, Zhubin, He, Rui , Harrison, Cynthia , Hergott, Christopher A. , Hsieh, Emily M. , Larson, Daniel P. , Lee, Benjamin J. , Leguay, Thibaut , Mangaonkar, Abhishek A. , Mezger, Kerstin, Pacenta, Holly , Provost, Marlie R. M., Puri, Latika, Raikar, Sunil S. , Martinez, Armando, Bristol, Isabella Quijada, Murphy, Kyle, Reiman, Lauren T. , Redell, Michele S. , Reed, Kelly, Guépin, Gabrielle Roth, Savaşan, Süreyya , Schafernak, Kristian T. , Stevens, Alexandra M. , Talleur, Aimee C. , Carapia, Naomi Torres, Vargaftig, Jacques , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Sasaki, Koji , Davis, Kara L. , Ghorashian, Sara , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Rankin, Alexander W , Semchenkova, Alexandra , Myers, Regina M , Zerkalenkova, Elena , Wang, Hao-Wei , Kovach, Alexandra E , Yuan, Constance M , Vasseur, Loïc , Alonso-Saladrigues, Anna , Balducci, Estelle , Aljudi, Ahmed Assim , Chang, Bill H , Cuevo, Raymund S , De Moerloose, Barbara , Dickens, David S , Duployez, Nicolas , Elliott, Michelle Ann, Harrison, Cynthia , Kim, Annette S , Kuo, Dennis J , Larson, Daniel P , Lee, Benjamin J , Leguay, Thibaut , Lindsley, R Coleman , Puri, Latika , Raikar, Sunil S , Rubinstein, Jeremy , Schafernak, Kristian , Talleur, Aimee , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Fabrizio, Vanessa A , Sasaki, Koji , Boissel, Nicolas , Rheingold, Susan R , Davis, Kara L , Ghorashian, Sara , Popov, Alexander , Shah, Nirali N , Silbert, Sara K. , Zerkalenkova, Elena , Colon, Dana Delgado, Bataller, Alex , Biery, D. Nathan, Chaer, Firas El , Grupp, Stephan A. , Pan, Jing , Martinez, Armando, Murphy, Kyle, Zhao, Liping, Aldoss, Ibrahim

Mayo Clinic

Blood | April 7, 2025 | Volume: 146 | Issue: 4 | Pages: 437-455

10.1182/blood.2024026655 | PMID 40193715 Get It

Abstract Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as “lineage drift” were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of <40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.
Medial Patellofemoral Ligament Reconstruction in Skeletally Immature Patients: A Systematic Review of Outcomes by Fixation Technique
Morgan, Vince K. , Warrier, Alec A. , Credille, Kevin , Wang, Zachary , Elias, Tristan J. , Haneberg, Erik , Yanke, Adam B. , Haneberg, Erik C , Hevesi, Mario

Mayo Clinic

Orthopaedic Journal of Sports Medicine | April 4, 2025 | Volume: 13 | Issue: 4 | Pages: No page available

10.1177/23259671251322724 | PMID 40190689 Get It

Background: Various medial patellofemoral ligament (MPFL) reconstruction techniques have been developed to minimize risks to the physis in skeletally immature patients. Purpose: To examine outcomes of MPFL reconstruction (MPFLR) based on fixation technique in skeletally immature patients. Study Design: Systematic review; Level of evidence, 4. Methods: PubMed, Scopus, Ovid, Cochrane Library, and CINAHL databases were searched for the literature on outcomes of MPFLR in the pediatric population, utilizing various anatomic and nonanatomic techniques. Primary outcomes were postoperative redislocation rates, return-to-sports (RTS) rates, and patient-reported outcomes (PROs). Moreover, outcomes involving sequela of growth plate disturbance were collected. Results: The final analysis included 17 studies—2 using sling-based techniques, 3 using surface-based techniques, 5 using soft tissue realignments, and 7 utilizing transosseous femoral fixations. Higher rates of postoperative redislocation were found in the sling-based (14.8%) and distal soft tissue realignment using semitendinosus tenodesis (38%) techniques, while lower rates were noted with surface-based (1.3%) and transosseous (3.4%) techniques. For PROs, there were large amounts of heterogeneity among studies, but all reported postoperative improvements, with more positive PROs generally seen in anatomic reconstructions. The RTS rate was 100% for surface-based techniques, 79.4% for distal soft tissue realignments, 79.5% for soft tissue realignment techniques, and 83.2% for transosseous techniques. No negative outcomes as a sequela of growth plate disturbance were reported. Conclusion: Nonanatomic techniques—such as sling-based and distal soft tissue realignment techniques—have higher rates of redislocation and lower RTS rates in skeletally immature patients undergoing MPFLR. Surface-based and transosseous tunnel-based techniques were shown to have lower redislocation and higher RTS rates. Clinical Relevance: This review provides insight into the most appropriate surgical management of patellar instability in patients with open growth plates.
Death From Infection Among Patients Living With Cancer
Chiam, Mckenzee , Mani, Kyle , Wang, Xi , Wang, Ming , Trifiletti, Daniel M. , Parent, Leslie J. , Spratt, Daniel E. , Tchelebi, Leila T. , Zaorsky, Nicholas G.

Mayo Clinic

American Journal of Clinical Oncology | April 3, 2025 | Volume: 48 | Issue: 7 | Pages: 327-335

10.1097/coc.0000000000001182 | PMID 40178912 Get It

Objectives: Early identification of patients living with cancer at higher risk of death from an infection is critical in infection mortality prevention. We characterize patients living with cancer at the highest risk of dying from an infection. Methods: 7,529,481 US cancer survivors (1992 to 2015) were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Standardized mortality ratios (SMRs) and 95% CIs were calculated. Fine-gray survival analysis was performed to calculate hazard ratios by adjusting for the effects of competing risks (eg, deaths due to causes other than infection). Results: Among 7,529,481 patients living with cancer (1992 to 2015), 101,167 (1.3%) died of infection. The rate of infection-specific mortality was 27.19/10,000 person-years, with an SMR of 3.29 (95% CI: 3.26-3.32, P <0.001). Patients who were older, male, black, and unmarried were at a greater risk of fatal infection. Overall, the risk of infection-specific mortality for patients living with cancer is greatest 1 year after diagnosis compared with the general population (SMR: 8.68, 95% CI: 8.53-8.84; P< 0.0001), and this risk decreases with follow-up time (SMR at >10 y after diagnosis: 2.93, 95% CI: 2.87-3.00; P< 0.0001). Among patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Kaposi Sarcoma, 9.2%, 11.5%, and 82.2% of all deaths within the first year after cancer diagnosis occurred due to acute infectious disease. In contrast, for patients with liver cancer, the relative percentage of infection-specific mortality increases with follow-up time from 3.5% at <1 year after cancer diagnosis and 10.4% at 10+ years of follow-up. Conclusion: The results of this study characterize infection mortality in patients living with cancer, which can guide more targeted research and interventions in this population.
Nuclear Galectin-1 promotes KRAS -dependent activation of pancreatic cancer stellate cells
Vinaixa, Judith , Gibert, Joan , Manero‐Rupérez, Noemí, Santofimia‐Castaño, Patricia , Baudou, Federico G. , Vera, Renzo E., Pease, David R. , Iglesias, Mar , Sen, Sandhya , Almada, Luciana L. , Marks, David L. , Fernández-Zapico, Martín E. , Navarro, Pilar , Santofimia-Castaño, Patricia , Iovanna, Juan , Rabinovich, Gabriel A , Navarro, Pilar , Martínez‐Bosch, Neus , Wang, Xiyin , Moreno, Mireia, Iovanna, Juan , Navarro, Pilar

Mayo Clinic

Proceedings of the National Academy of Sciences | April 2, 2025 | Volume: 122 | Issue: 14 | Pages: No page available

10.1073/pnas.2424051122 | PMID 40172967 Get It

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, primarily due to its complex tumor microenvironment (TME), which drives both disease progression and therapy resistance. Understanding the molecular mechanisms governing TME dynamics is essential for developing new treatment strategies for this devastating disease. In this study, we uncover an oncogenic role for Galectin-1 (Gal1), a glycan-binding protein abundantly expressed by activated pancreatic stellate cells (PSCs), a key component of the PDAC TME that orchestrates tumor progression. Our findings reveal that Gal1 expression is elevated in the nucleus of human PSCs in both tissue samples and cultured cell lines. Using chromatin immunoprecipitation followed by sequencing analysis (ChIP-seq), we identify Gal1 occupancy at the promoters of several cancer-associated genes, including KRAS , a pivotal oncogene involved in PDAC pathogenesis. We demonstrate that Gal1 binds to the KRAS promoter, sustaining KRAS expression in PSCs, which, in turn, maintains PSC activation and promotes the secretion of protumorigenic cytokines. Mechanistically, Gal1 is required to preserve histone H3 lysine 4 monomethylation levels and to recruit the histone methyltransferase MLL1 to target promoters. Collectively, our findings define a nuclear function of Gal1 in modulating the transcriptional landscape of cancer-associated genes in PSCs within the PDAC TME, mediated through an epigenetic mechanism. These insights enhance our understanding of PDAC pathology and open potential avenues for therapeutic interventions targeting intracellular Gal1.
ICU Outcome Predictions Using Real-Time Signals with Wavelet-Transform-based Deep Learning Method
Jiang, Yiqun , Wang, Shaodong , Zhang, Wenli , Li, Qing

Mayo Clinic

ACM Transactions on Management Information Systems | April 2, 2025 | Volume: 16 | Issue: 4 | Pages: 1-29

10.1145/3727624 Get It

Intensive care units (ICUs) serve patients with life-threatening conditions. However, the availability of ICU resources remains scarce worldwide. Therefore, it is critical to conduct ICU outcome predictions at an early stage and promote efficient use of ICU resources. However, the current ICU outcome prediction methods have limitations such as unsatisfactory accuracy and dependence on resource-demanding laboratory tests or expert domain knowledge. In this research, we design a wavelet transform based additive convolutional neural network (WT-A-CNN) that requires only patients’ vital sign series and information at ICU admission for real-time ICU outcome predictions. The model is evaluated using a large real-world ICU database and outperforms state-of-the-art baselines on both ICU mortality and length-of-stay prediction tasks. Furthermore, the additive structure of the model can be used for model interpretation and analyzing which input signal is more useful for ICU outcome prediction for different patient cohorts. Our work provides an efficient tool for ICU outcome predictions, allowing healthcare providers to act promptly on patients at risk and reduce the negative impacts on patient outcomes.